Stock Financial Ratios


CTIC / CTI BioPharma Corp. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price2.76
Volume37,300.00
Market Cap ($M)118.77
Enterprise Value ($M)28.11
Book Value ($M)13.32
Book Value / Share0.48
Price / Book3.48
NCAV ($M)23.20
NCAV / Share0.83
Price / NCAV2.04
Income Statement (mra) ($M)
Revenue57.41
EBITDA-49.16
Net Income-52.95
Balance Sheet (mrq) ($M)
Cash & Equivalents52.80
Cash / Share1.89
Assets65.53
Liabilities37.12
Quick Ratio1.34
Current Ratio1.37
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-2.49
Return on Assets (ROA)-0.83
Return on Equity (ROE)-3.98
Identifiers and Descriptors
CUSIP12648L106
Central Index Key (CIK)891293
Industry Groups
SIC 2834 - Pharmaceutical Preparations
Other Related CUSIPS
12648L906
12648L601
12648L956
Share Statistics
Common Shares Outstanding (M)42.97
Scoring Models
Piotroski F Score6.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Inventory Raw Materials Per Share0.00
Accounts Receivable Per Share0.01
Liabilities Per Share1.33
Liabilities Current Per Share0.94
Assets Other Current Per Share0.00
Accounts Payable Per Share0.00
Equity Per Share1.22
Cash Per Share1.89
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Property Plant And Equipment Net Per Share0.09
Inventory Work In Progress Per Share0.00
Debt Per Share0.28
Additional Paid In Capital Per Share0.00
Long Term Debt Per Share0.25
Treasury Stock Per Share0.00
Assets Other Non Current Per Share0.20
Liabilities And Stock Equity Per Share2.34
Cash And Equivalents Per Share1.89
Intangibles Per Share0.00
Assets Current Per Share2.06
Property Plant And Equipment Per Share0.09
Inventory Finished Goods Per Share0.01
Accumulated Depreciation And Depletion Per Share0.00
Goodwill Per Share0.00
Current Portion Of Long Term Debt Per Share0.28
Minority Interest Per Share-0.20
Retained Earnings Per Share-78.72
Liabilities Other Non Current Per Share0.11
Deferred Income Tax Liabilities Per Share0.00
Assets Per Share2.34
Inventory Per Share0.02
Property Plant And Equipment Gross Per Share0.00

Related News Stories

CTI BioPharma's (CTIC) CEO Adam Craig on Q3 2017 Results - Earnings Call Transcript

2017-11-07 seekingalpha
Good day and welcome to the CTI BioPharma Third Quarter 2017 Financial Results Conference Call. Today's conference is being recorded. At this time, I would like to turn the conference over to Ed Bell, Investor Relations. Please go ahead, sir. (11-0)

BRIEF-CTI Biopharma reports third quarter 2017 financial results

2017-11-06 reuters
* CTI Biopharma Corp - ‍total revenues for q3 were $1.7 million compared to $4.4 million Source text for Eikon: Further company coverage: (11-0)

Insight From The Stellar Scientist Trader - An Integrated BioSci Investing Report

2017-10-25 seekingalpha
In the previous week, Dr. Tran BioSci of Integrated BioSci Investing had the honor to sit down with the expert, Decision Analytics in an interview. Our readers greatly benefited from his wisdom. His recommendation on Spectrum Pharmaceuticals (NASDAQ:SPPI) proved correct. The stock increased 36% the following day (and reached its 52-weeks high) after the accurate forecasting of the phase 2 trial (which studied poziotinib as a treatment for non small cell lung cancer with exon 20 mutation). (372-5)

BRIEF-CTI Biopharma appoints Laurent Fischer as new board chairman

2017-09-26 reuters
* CTI Biopharma appoints Laurent Fischer as new chairman of the board and announces management promotions (11-0)

CTI BioPharma Appoints Laurent Fischer as New Chairman of the Board and Announces Management Promotions

2017-09-26 prnewswire
SEATTLE, Sept. 26, 2017 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA: CTIC) today announced that Laurent Fischer, M.D. has been appointed its new Chairman of the Board and the promotion of David H. Kirske to Chief Financial Officer and Bruce J. Seeley to Chief Operating Officer of the company. (98-0)

CUSIP: 12648L106